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A Randomized Phase II Trial of Two Schedules of Docetaxel
in Elderly or Poor Performance Status Patients with
Advanced Non-small Cell Lung Cancer
Rogerio Lilenbaum, MD,* Mark Rubin, MD,† Joyce Samuel, MD,‡ Laszlo Boros, MD,§
Tarek Chidiac, MD,¶ Leonard Seigel, MD, Afshin Dowlati, MD,# Patricia Graham, BA, CCRP,**
Jennifer Beaumont, MS,†† and Hongyan Du, MS††
Background:We conducted a multicenter randomized phase II trial
to evaluate two schedules of single-agent docetaxel in the first-line
treatment of elderly and performance status (PS) 2 patients with
advanced non-small cell lung cancer (NSCLC).
Methods: Patients 70 years of age and older with a PS 0–1 or
patients of any age and PS 2 were randomly assigned to docetaxel 75
mg/m2 on day 1 every 3 weeks or 30 mg/m2 on days 1, 8, and 15
every 28 days. The primary end point was frequency of grade 3/4
toxicities. Health-related quality of life, response, and survival were
secondary end points.
Results: Fifty-five patients were randomized to received docetaxel
every 3 weeks and 56 to receive docetaxel weekly. Hematologic
toxicity, primarily grade 3/4 neutropenia, was significantly lower in
the weekly schedule (0% versus 44%; p  0.001). Health-related
quality of life was similar between the two arms. Efficacy parame-
ters were not significantly different, with a trend toward better
survival in the weekly schedule group (6.7 versus 3.5 months).
Patients with PS 0–1 had a significantly longer survival compared
with PS 2 patients (7.8 versus 2.9 months; p  0.001). A subset
analysis of 30 octogenarian patients revealed similar outcomes as in
70- to 79-year-old patients.
Conclusion: Weekly docetaxel is associated with less neutropenia
and a trend toward improved survival in elderly or PS 2 patients. PS
rather than age is the primary determinant of outcome in this
population. Octogenarians benefited from weekly docetaxel. Future
studies should separate elderly patients from PS 2 patients.
Key Words: Advanced non-small cell lung cancer, Docetaxel,
Elderly.
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The treatment of advanced non-small cell lung cancer(NSCLC) has evolved substantially over the past decade.
Chemotherapy with a platinum-based doublet prolongs survival
and improves quality of life in patients with good performance
status (PS).1 Recently, the addition of bevacizumab and oral
epidermal growth factor receptor (EGFR) tyrosine kinase inhib-
itors in appropriately selected patients have improved the out-
come of patients with advanced NSCLC.2,3
Elderly patients and patients with PS 2 have been
historically excluded from large randomized clinical trials,
and limited evidence-based data are available to guide the
management of these subgroups.4 As a result, treatment
strategies vary considerably, ranging from best supportive
care to combination chemotherapy.
Single-agent therapy remains a valid option for the
treatment of elderly patients.5 A large Italian study failed to
demonstrate a benefit for combination therapy over single-
agent therapy.6 This is in contrast to subset analyses of large
randomized trials that suggest that elderly patients with good
PS benefit from combination chemotherapy.7,8 For patients
with PS 2, data are more scant and no randomized trial com-
paring single-agent with combination chemotherapy has been
reported in this subgroup. The most recent American Society of
Clinical Oncology guidelines recommended single-agent ther-
apy for the treatment of elderly and PS 2 patients.9
Docetaxel is an active single-agent in second-line therapy,
and in combination with a platinum analogue in first-line ther-
apy. A recent Japanese randomized trial compared single-agent
docetaxel with vinorelbine and found improvements in several
efficacy end points with docetaxel, although the difference in
overall survival (OS), although clinically meaningful, did not
reach statistical significance.10 However, when docetaxel is
administered in the standard every 3-week schedule, myelosup-
pression can be severe and often requires hematopoietic growth
*Mount Sinai Cancer Center, Miami Beach, FL; †Florida Cancer Specialists,
Bonita Springs, FL; ‡Cook County Hospital, Chicago, IL; §Interlakes
Oncology and Hematology, Rochester, NY; ¶Mid Ohio Oncology He-
matology, Columbus, OH; Holy Cross Hospital, Ft. Lauderdale, FL;
#University Hospitals of Cleveland, Cleveland, OH; **Sarah Cannon
Cancer Center, Nashville, TN; ††Center on Outcomes, Research and
Education, Evanston, IL.
Disclosure: Rogerio Lilenbaum has received research support and is a
consultant for Sanofi-Aventis. The authors declare no other conflict of
interest.
This study was presented in abstract form at the 40th Annual Meeting of the
American Society of Clinical Oncology (ASCO), May 2004. This manu-
script is an original report.
Address for correspondence: Rogerio Lilenbaum, MD, Mount Sinai Cancer
Center; 4306 Alton Road, Miami Beach, FL 33140. E-mail: rlilenbaum@
aptiumoncology.com.
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0204-0306
Journal of Thoracic Oncology • Volume 2, Number 4, April 2007306
factor support. Clinical trials using docetaxel on a weekly
schedule showed less hematologic toxicity, but specific nonhe-
matologic toxicities tend to be more pronounced.11 Randomized
trials conducted in Europe in second-line therapy have shown
comparable efficacy between the two schedules and lesser over-
all toxicity on the weekly schedule.12–14 Practice among U.S.
oncologists varies considerably, and no comparative trial of
first-line therapy has been performed.
The optimal schedule of docetaxel is particularly rele-
vant for elderly and PS 2 patients who tend to tolerate
treatment poorly compared with younger patients and patients
with good PS. Therefore, we designed a phase II randomized
trial of docetaxel weekly versus every 3 weeks in the treat-
ment of these two subgroups to assess the impact of schedule
on toxicity and quality of life. We chose to adopt the schedule
of three consecutive weekly treatments, every 4 weeks, rather
than the original 6 out of 8 weeks because significant fatigue
was reported with the latter schedule in our previous study.15
Furthermore, in one of the three phase III randomized trials
cited above, the 3 out of 4-week schedule was also used.14
PATIENTS AND METHODS
Eligibility
Patients with cytologic or histologic confirmation of
stage IIIB (malignant effusion) and IV NSCLC, at least 70
years of age if PS was 0–1, or any age if PS was 2 as assessed
by Eastern Cooperative Oncology Group criteria. Previous
chemotherapy was not allowed. Patients with locally ad-
vanced disease amenable to combined modality therapy were
not eligible. Previous radiation was allowed, and toxicities
had to be grade 2 or less before entry. Patients with brain
metastases were eligible if neurologically stable after appro-
priate therapy. Adequate organ function was required. Pa-
tients with grade 2 peripheral neuropathy or a history of
hypersensitivity to taxanes or polysorbate 80 were not eligi-
ble. Patients with concurrent active malignancies, except in
situ carcinoma of the cervix and basal cell carcinoma of the
skin, were not eligible. Approval by the institutional review
board at each participating institution was required. All pa-
tients signed informed consent.
Treatment Plan
Patients from 25 participating centers were randomly
assigned to treatment with docetaxel administered intrave-
nously over 1 hour at a dose of 75 mg/m2 every 3 weeks or
to docetaxel administered intravenously over 30 minutes at a
dose of 30 mg/m2 on days 1, 8, and 15 every 28 days. Patients
in both arms received premedication with dexamethasone.
Both treatments were repeated for a maximum of six cycles.
Randomization was centralized at Theradex in Princeton, NJ,
and was stratified by stage (IIIB versus IV), age (older than
70 versus 70 and younger), and PS (0–1 versus 2). Supportive
care, including antiemetics and growth factors, was at the
discretion of the treating physician.
Toxicity was assessed every cycle using National Can-
cer Institute Common Toxicity Criteria. Dose modifications
included one reduction to docetaxel 65 mg/m2 every 3 weeks
and docetaxel 25 mg/m2 weekly, and a second dose reduction
to 55 mg/m2 and 20 mg/m2, respectively. If a third dose
reduction was required, the patient was removed from study
therapy. Dose reductions were recommended for grade 4
neutropenia lasting more than 5 days, febrile neutropenia,
thrombocytopenia to less than 50,000, grade 2 neurotoxicity
(grades 3 and 4 mandated discontinuation of study therapy),
and grade 3/4 stomatitis. No dose reduction was suggested for
fluid retention, nausea/emesis, hypersensitivity reactions, or
excessive lacrimation. Treatment was withheld up to 3 weeks
for any grade 3 or 4 toxicity until the patient recovered to
grade 2 or less. Administration of growth factors was at
investigators’ discretion.
Response was assessed by imaging studies every two
cycles and evaluated by the Response Evaluation Criteria in
Solid Tumors. A complete response was defined as disap-
pearance of all target lesions. A partial response was defined
as at least a 30% decrease in the sum of the longest diameter
(LD) of target lesions, taking as reference the baseline sum
LD. Progressive disease was defined as at least a 20%
increase in the sum of the LD of target lesions, taking as
reference the smallest sum LD recorded since the treatment
started or the appearance of new lesions. Stable disease was
defined as neither sufficient decrease to qualify for partial
response nor sufficient increase to qualify for progressive
disease, taking as reference the smallest sum LD since the
treatment started. For nontarget lesions, complete response
was defined as disappearance of all nontarget lesions; incom-
plete response/stable disease was defined as persistence of
one or more nontarget lesion(s), and progressive disease was
defined as appearance of new lesions and/or unequivocal
progression of existing nontarget lesions. Health-related qual-
ity of life was assessed using the Functional Assessment of
Cancer Therapy-Lung (FACT-L).16
Statistical Analysis
The primary objective was to compare the incidence of
grade 3/4 toxicities between the two schedules of docetaxel.
Additional outcomes included overall toxicities, quality of
life, and efficacy, including response rate, time to progression
(TTP), and OS. Assuming a 36% incidence of at least one
grade 3/4 toxicity in patients treated with docetaxel every 3
weeks, a 50% reduction in patients treated with weekly
docetaxel required 106 patients per arm to detect a difference
with 80% power at the 95% significance level. Logistic
regression analysis was used to compare grade 3/4 toxicity
between treatment arms, while adjusting for stratification
factors (age, PS). Response rates and incidence of other grade
2–4 relevant toxicities were similarly compared. TTP was
calculated as the time from randomization until first occur-
rence of tumor progression or death. Patients who withdrew
from the study before an event or remained event free at the
end of the study were censored at the date of their last
nonprogressive tumor assessment. OS was calculated as time
from randomization until death from any cause. If a patient
was known not to have died, survival was censored at the
time of last contact. TTP and OS were compared between
treatment arms using a Cox proportional hazards model.
Analyses were based on intent to treat and included all
randomized patients.
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The FACT-L was scored according to standard scoring
algorithms such that a higher score represents better quality
of life. The FACT-L Trial Outcome Index (TOI), the sum of
the physical well-being, functional well-being, and lung can-
cer–specific subscales was the primary quality of life out-
come. Research indicates that a 5- to 7-point difference in
TOI scores is required for clinically meaningful change.17
The analyses of the FACT-L involved summary measures
for longitudinal data. Change scores were calculated for
the TOI by subtracting each patient’s baseline score from
their score at each subsequent assessment. We used gen-
eral linear models to compare average change scores
between treatment arms.
The effect of age and PS on all outcomes was assessed
by comparison of groups classified by PS (PS 0–1 versus PS
2) and age (younger than 70 versus 70 and older). Additional
exploratory analyses were performed in subgroups of patients
based on age and PS.
RESULTS
Baseline Characteristics
A total of 111 patients were randomized between May
of 2002 and March of 2004 to received docetaxel every 3
weeks (n  55) or weekly (n  56). The rate of accrual
decreased over time, and the trial was stopped before reach-
ing its target. There were no differences between the two
arms in baseline characteristics (Table 1). Five patients, three
assigned to docetaxel every 3 weeks and two assigned to
weekly docetaxel, were not treated with study drug due to
death before the start of treatment (two patients) or with-
drawal of consent after randomization (three patients). A
median of 2.5 and two cycles were administered in the every
3 weeks arm and weekly arm, respectively. Thirty-six pa-
tients (17 every 3 weeks, 19 weekly) required dose delay or
reduction. Median dose intensity was 25 mg/m2/week in the
every 3 weeks arm and 22.5 mg/m2/week in the weekly arm.
Toxicity
Grade 3/4 neutropenia was present in 44% in the every
3 week schedule and 0% in weekly schedule (p 0.001). For
combined grade 3/4 anemia, neutropenia, or thrombocytope-
nia, the figures were 44% and 4%, respectively. One episode
of grade 2 febrile neutropenia was observed in the 3-week
arm. The incidence of other grade 2–4 toxicities was not
significantly different between the two arms (Table 2). There
was no difference between the incidence of hematologic and
nonhematologic toxicities between patients with PS 0–1 and
PS 2 or between patients older and younger than 70 years of
age.
Efficacy
Of the 106 patients treated with study drug, 12 were not
assessable for response. The overall response rate was 9.1%
in the every 3 weeks schedule versus 5.4% in the weekly
schedule in the ITT population (Table 3). The figures for
assessable patients were 10.9% and 6.3%, respectively (p 
TABLE 2. Percentage of Patients with Selected Toxicities of
Grade 2 or Higher in the As-Treated Study Population
Docetaxel
Every 3 wk
(n  52)
Weekly
(n  54) p
Hematologic toxicities, no. (%)
Neutropenia 24 (46) 0 0.001
Anemia 8 (15) 10 (19) 0.668
Thrombocytopenia 0 1 (2) 1.00
Nonhematologic toxicities, no. (%)
Dyspnea 15 (29) 24 (44) 0.096
Fatigue 16 (31) 12 (22) 0.318
Diarrhea 9 (17) 6 (11) 0.360
Nausea and vomiting 7 (13) 8 (15) 0.842
Dehydration 8 (15) 6 (11) 0.516
Edema 4 (8) 4 (8) 1.00
Infection, sepsis, febrile neutropenia 4 (8) 3 (6) 0.713
TABLE 1. Baseline Patient Characteristics
Docetaxel
Every 3 wk
(n  55)
Weekly
(n  56)
Total
(n  111)
Gender, no. (%)
Male 32 (58) 32 (57) 64 (58)
Female 23 (42) 24 (43) 47 (42)
Age, yr, median (range) 75 (53–86) 75 (46–86) 75 (46–86)
Age 80 yr, no. (%) 13 (24) 17 (30) 30 (27)
Stratification group, no. (%)
Age 70 yr, PS 0 or 1 27 (49) 26 (46) 53 (48)
Any age, PS 2 28 (51) 30 (54) 58 (52)
ECOG PS, no. (%)
0 5 (9) 6 (11) 11 (10)
1 22 (40) 20 (36) 42 (38)
2 28 (51) 30 (54) 58 (52)
Stage of disease, no. (%)
IIIB 8 (15) 10 (18) 18 (16)
IV 47 (85) 46 (82) 93 (85)
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
TABLE 3. Best Response to Therapy
Docetaxel
Every 3 wk
(n  55)
Weekly
(n  56)
Complete response 1 (1.8) 0
Partial response 4 (7.3) 3 (5.4)
Stable disease 20 (36.4) 21 (37.5)
Progressive disease 21 (38.2) 24 (42.9)
Not assessable 9 (16.4) 8 (14.3)
Overall response rate* 5 (9.1) 3 (5.4)
Disease control rate
Number (%) shown.
*Odds ratio (95% confidence interval)  1.8 (0.4–7.8); p  0.452.
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0.428). For patients with PS 0–1, response rate was 10.6%
versus 6.4% for those with PS 2 (p  0.464).
Median TTP was 1.7 and 2.3 months for every 3 weeks
docetaxel schedule and weekly docetaxel schedule, respec-
tively (p  0.549; Figure 1). Patients with PS 0 or 1 had
longer TTP than patients with PS 2 (3.1 versus 1.6 months
respectively; p  0.043). When age, PS, and treatment arm
were included in a Cox proportion hazard regression model,
only PS was significantly related to TTP (p  0.006; hazard
ratio  2.2). In both the PS 2 and PS 0–1 cohorts individu-
ally, there was no difference in TTP between the two arms
(p  0.384 and 0.784, respectively).
Survival information was not available for two patients
(both in the every 3 weeks schedule) who were therefore
censored at randomization. Median survival for the overall
population was 5.3 months (95% confidence interval: 3.5–
7.1). Median survival was 3.5 months in the every 3 weeks
and 6.7 months in the weekly schedules (p  0.581; Figure
2). Patients with PS 0–1 had a superior survival compared to
PS 2 patients: 7.8 versus 2.9 months (p  0.001, Figure 3).
Patients younger than 70 years of age had longer survival
compared with older patients: 6.3 versus 2.9 months (p 
0.047). Only PS was significantly related to survival in the
Cox model (p  0.001; hazard ratio  2.2). In both the PS 2
and PS 0–1 cohorts, there was no difference in survival
between the two arms.
Health-related Quality of Life
One hundred four patients (94%) completed a FACT-L
questionnaire at baseline. Compliance was variable through-
out the study, with only a 65% rate of completion in the
second cycle. Descriptive statistics for the FACT-L TOI at
baseline are shown in Table 4, and the trend over time is
shown in Figure 4. The average change in TOI scores within
treatment arms (2.4 in the every 3 weeks schedule and2.3
in the weekly schedule) did not exceed the threshold for a
minimally important difference. TOI average change from
baseline scores did not differ across age or PS groups.
Exploratory Subset Analyses
For exploratory analyses, patients were divided into
four subgroups in an attempt to sort out the effect of age and
PS: Patients younger than 70 years of age with PS 2 (n 28),
patients between the ages of 70 and 79 with PS 0–1 (n 29),
patients between the ages of 70 and 79 with PS 2 (n  24),
and octogenarians with any PS (n  30). The incidence of
hematologic toxicities across the four subgroups was similar
and consistently higher in the every 3 weeks schedule. The
FIGURE 1. Kaplan-Meier estimates of time to progression.
FIGURE 2. Kaplan-Meier estimates of overall survival.
FIGURE 3. Kaplan-Meier estimates of overall survival by
performance status (PS).
FIGURE 4. Functional Assessment of Cancer Therapy-Lung
(FACT-L) Trial Outcome Index (TOI).
TABLE 4. Health-related Quality of Life
Docetaxel
Every 3 wk
(n  55)
Weekly
(n  56) p
Baseline FACT-L TOI scores,
mean (SD)
50.2 (12.5) 49.8 (15.7)
Average change from baseline in
FACT-L TOI scores, mean (SD)
2.4 (10.9) 2.3 (13.6) 0.056
FACT-L TOI, Functional Assessment of Cancer Therapy-Lung Trial Outcome
Index.
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overall response rate was not significantly different across the
four subgroups. All subgroups experienced a slight trend
toward longer TTP and OS in the weekly arm compared with
the every 3 weeks arm, but numbers were too small for
adequate comparisons.
Octogenarians were a focus of the subset analyses. A
total of 30 patients were randomized and 27 treated in the
protocol. Approximately 20% had PS 2 and 80% had stage IV
at baseline. There were two partial responses (7.4%), both in
patients with PS 0–1. Both TTP (2.6 versus 1.9 months) and
OS (7.8 versus 5.3 months) were numerically superior in the
octogenarian subgroup compared with the overall study pop-
ulation. Further, TTP was slightly better in the weekly com-
pared with the every 3 weeks schedule (4.3 versus 2.6
months), as was OS (9.4 versus 7.8 months). No notable
differences existed between octogenarians with PS 0–1 and
PS 2 with respect to survival, but only six of the 30 enrolled
patients had PS 2.
DISCUSSION
To our knowledge, this is the first phase II randomized
trial of two schedules of single-agent docetaxel in the first-
line treatment of elderly and PS 2 patients with advanced
NSCLC. Although it has become increasingly evident that
elderly and PS 2 patients have different characteristics and
present distinct management challenges, at the time this study
was conceived, both subsets were considered special popu-
lations, primarily because of a lack of evidence-based data
available from large cooperative group randomized trials. In
this report, we attempt to better characterize these two sub-
groups and their outcome with single-agent therapy.
Three randomized trials comparing docetaxel adminis-
tered weekly versus every 3 weeks in previously treated
patients have been published.12–14 The study by Gridelli and
colleagues,12 which included 220 patients, used a weekly
dose of 33.3 mg/m2 weekly for 6 weeks. Response and
survival rates were similar between the two arms. Quality of
life as measured by daily diary cards was superior for weekly
therapy, which the authors recommended as the preferred
schedule. The study by Camps and colleagues13 randomized
259 patients to an every 3 weeks or a weekly schedule at a
dose of 36 mg/m2 for 6 weeks. Despite a slight difference in
median survival in favor of the standard schedule (6.6 versus
5.4 months; p  0.075), the median TTP and OS were
similar. The authors recommended the weekly schedule for
patients at risk of severe neutropenia. In the study by Schuette
and colleagues,14 215 patients received docetaxel at 75
mg/m2 every 3 weeks or at 35 mg/m2 on days 1, 8, and 15.
Efficacy parameters were similar, but the weekly schedule
was better tolerated with a lower incidence of grade 3/4
toxicities.
Our results indicate that toxicity indeed differed be-
tween the two schedules. Hematologic toxicity, in particular,
neutropenia, was significantly lower on the weekly schedule.
However, the incidence of severe infectious complications
did not seem to be significantly different. The frequency of
anemia was similar, and thrombocytopenia was equally rare
in both arms. Initial concerns about toxicities peculiar to the
weekly schedule, such as excessive lacrimation, nail dystro-
phy, and diarrhea,18 were not observed in our study. Perhaps
the duration of therapy, with a median of two cycles in our
trial, was not sufficiently long to cause these cumulative
toxicities.
Our results indicate that both schedules have similar
efficacy in the elderly and PS 2 patients. Although response
and survival rates seemed lower than expected, the confi-
dence intervals overlap with previously reported results in a
similar patient population.19,20 More importantly, in a pre-
specified analysis, there was a significant difference in sur-
vival between elderly patients with PS 0–1 compared with
patients with PS 2, supporting the concept that PS rather than
age has the greatest impact on prognosis. Moreover, in the PS
2 cohort, median survival was numerically superior for those
treated with the weekly schedule (4 versus 2 months). Al-
though the study was not powered to detect differences in
survival and in fact did not reach its prespecified accrual,
these figures are provocative and potentially useful in guiding
further research and decisions in clinical practice. In fact,
weekly docetaxel has been adopted as a template for an
ongoing CALGB phase II randomized trial in combination
with cetuximab or bortezomib in the first-line treatment of PS
2 patients.
The quality-of-life analysis showed no significant dif-
ference between the two arms. Interestingly, the overall TOI
scores improved slightly for patients in the every 3 weeks arm
and declined in the weekly arm, despite similar efficacy
between the two arms and decreased toxicity on the weekly
schedule. For patients who completed the FACT-L assess-
ment on the fourth cycle (17 in the every 3 weeks arm and 15
in the weekly arm), the mean scores were significantly better
than baseline, presumably because these are the patients who
benefited the most from therapy. Our study did not include an
analysis of comorbidity or functional status, which, in addi-
tion to PS, may also be useful in stratifying compromised
patients for chemotherapy.21
The exploratory analyses confirm that age does not
appear to be an impediment to chemotherapy. There are very
few data, however, on octogenarian patients with advanced
NSCLC. A recent combined analysis of our own trial and the
Southwest Oncology Group trial22 suggested that selected
octogenarians are able to tolerate single-agent therapy. Inter-
estingly, this analysis showed that for octogenarians with a
good PS (0–1), the median survival was inferior to patients
aged 70–79 with the same PS, suggesting an effect of age
and/or comorbidities. In fact, limited data from the Eastern
Cooperative Oncology Group trial 1594, with only nine
patients older than the age of 80 showed a poor outcome,
comparable with PS 2 patients.23 In our trial, a trend toward
improvement in survival for the weekly arm was noted
among octogenarians, which we suggest as the preferred
schedule for this patient population. Clearly, further dedi-
cated studies are needed in these patients.
In summary, elderly patients seemed to benefit from
single-agent docetaxel provided their PS was acceptable. The
results for PS 2 patients are in line with those of other
single-agent trials in this subset. A trend toward better out-
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come with the weekly schedule was noted. Octogenarians
derived similar benefit compared with other elderly patients.
Our results help clarify important differences between elderly
and PS 2 patients and provide a framework for the treatment
of these patients in clinical practice.
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